Strategically Responding to Manufacturer Inquiries
Responding to Manufacturer Inquiries with Avanti340B: A Proven Solution for Covered Entities
In today’s rapidly evolving political and economic landscape, covered entities are experiencing a sharp increase in inquiries from pharmaceutical manufacturers regarding 340B purchasing patterns. These requests — often delivered directly or through third-party audit vendors — are becoming more frequent, more detailed, and more urgent.
A key challenge for covered entities in responding to such inquiries is that manufacturer data typically reflects only one side of the transaction. Without insight into the entity’s internal records, these data sets can present an incomplete or misleading picture of purchasing and dispensing behavior.
Avanti340B bridges that gap.
Run quarterly, Avanti340B offers a comprehensive, entity-wide view of 340B drug purchases and dispenses. By consolidating data across systems and providing clear, actionable visualizations, Avanti340B equips covered entities with the tools they need to present a complete, transparent response. The platform supports consistent data validation and review, ensuring that entities are always prepared to respond confidently to manufacturer inquiries — whether informal, in the context of a good faith inquiry, or during more formal audit processes.
How Avanti340B Helps
Closes the data gap between manufacturer purchase records and entity-level dispensing records.
Presents multi-year purchasing and dispensing trends in a streamlined, professional format.
Improves response time and enhances credibility during manufacturer reviews or disputes.
Supports good faith dialogue with clear and validated evidence.
case studies
Case Study 1: Resolving a Multi-Year Inquiry from a Top-10 Manufacturer
A large health system received a multi-year inquiry from a major pharmaceutical manufacturer regarding unusually high volumes of a specific oncology drug. Using Avanti340B, the system compiled three years of purchase and dispense data, aligning transactions to show consistent eligibility. The data visualization tools in Avanti340B helped the entity present the timeline and context clearly, which led to a swift resolution without escalation.
Case Study 2: Addressing Discrepancies in Contract Pharmacy Purchases
One of our clients, a community health center, was flagged for potential duplicate discounts due to contract pharmacy activity. By using Avanti340B, the entity demonstrated appropriate separation of Medicaid and 340B claims across its dispensing partners. The visuals and transaction-level reports generated by the platform enabled the entity to clarify its compliance protocols, ultimately avoiding further scrutiny and maintaining manufacturer trust.
Case Study 3: Supporting a Good Faith Inquiry Involving a Mixed Use Drug A rural hospital was contacted by a manufacturer representative questioning the 340B purchase patterns of a therapy used in both inpatient and outpatient settings. The hospital used Avanti340B to quickly pull dispense-level data and show that the product had been used exclusively for eligible outpatient patients. The prompt and transparent response, supported by Avanti340B reporting, resulted in the closure of the inquiry within two weeks.
Conclusion
Avanti340B empowers covered entities to respond to manufacturer inquiries with confidence and clarity. By offering a complete, verified picture of drug utilization and purchase behavior, the platform reduces risk, enhances transparency, and supports long-term compliance.
If your organization is facing increased manufacturer scrutiny, Avanti340B can be an essential part of your response strategy.